Methylene Blue
Methylene blue scores 6.2/10: strong as an FDA-approved methemoglobinemia antidote and an acute mitochondrial redox tool, but healthy-user nootropic evidence is still thin despite human fMRI signals from Rodriguez 2016.
Methylene Blue scored 5.1 / 10 (⚖️ Neutral) on the BioHarmony scale as a Substance → Pharmaceutical / Drug.
What It Is
Methylene blue is methylthioninium chloride, a synthetic phenothiazine dye that doubles as a redox-active drug. In medicine, DailyMed labeling positions IV methylene blue as an oxidation-reduction agent for acquired methemoglobinemia. In the biohacking world, the same molecule is used off-label at much lower oral or sublingual doses for energy, mental clarity, and mitochondrial support.
The cleanest clinical evidence is not the nootropic use case. Rothenberg 2025 supports effectiveness and tolerability for methemoglobinemia over a long poison-center experience. Huang 2024 found shorter mechanical ventilation, ICU stay, and hospital stay in distributive-shock RCTs, while Zhu 2025 and Zhang 2025 support local injection in procedure-specific pain contexts. Those are legitimate medical signals, but they do not prove that 1-5 mg oral microdosing transforms healthy cognition.
The wellness case rests on mitochondrial redox cycling and small human brain-imaging trials. Rodriguez 2016 reported increased task-related functional MRI responses and a 7% short-term memory retrieval improvement after one 280 mg oral dose in 26 healthy adults. Rodriguez 2016 functional-connectivity data also showed acute network changes. That earns methylene blue a real but limited nootropic signal.
The downside is unusually important for a compound sold in wellness circles. Ramsay 2007 confirmed methylene blue as a potent reversible MAO-A inhibitor, and the FDA safety communication warns about serious central-nervous-system reactions when methylene blue is used with serotonergic psychiatric medications. Basically: methylene blue is useful enough to be interesting, but drug-like enough to deserve drug-level respect.
Terminology
For a clinical cross-reference, see the NCBI StatPearls methylene blue monograph.
- MB: Methylene blue, also called methylthioninium chloride.
- USP: United States Pharmacopeia. A pharmaceutical purity standard relevant to human-use sourcing.
- ETC: Electron Transport Chain. The mitochondrial inner-membrane system that moves electrons to help make ATP.
- ATP: Adenosine triphosphate. The cell's main energy currency.
- NADH: Reduced nicotinamide adenine dinucleotide. An electron donor feeding mitochondrial energy production.
- MAOI / MAO-A: Monoamine oxidase inhibitor / monoamine oxidase A. MAO-A inhibition is central to methylene blue's serotonin-toxicity concern.
- SSRI / SNRI: Selective serotonin reuptake inhibitor / serotonin-norepinephrine reuptake inhibitor. Common antidepressant classes that can interact dangerously with methylene blue.
- G6PD: Glucose-6-phosphate dehydrogenase. Deficiency raises hemolytic-anemia risk with oxidant drugs.
- Methemoglobinemia: A condition where hemoglobin iron cannot carry oxygen normally; IV methylene blue is an approved treatment.
- BOLD: Blood oxygen level dependent. A functional MRI signal used as a proxy for changes in brain activity.
- fMRI: Functional magnetic resonance imaging. Brain imaging used in the Rodriguez methylene blue studies.
- LMTX / TRx0237: Methylthioninium derivative studied as a tau-aggregation inhibitor in Alzheimer's disease trials.
- Pulse oximetry: The finger oxygen-saturation measurement that methylene blue can distort after dosing.
- 503A: U.S. compounding-pharmacy classification for patient-specific prescription compounds.
- WADA: World Anti-Doping Agency. No explicit methylene blue listing was found in the audit, but athletes should verify product-specific status.
Dosing & Protocols
Dosing information is summarized from published research and community reports. This is not a prescribing guide. Consult a healthcare provider before starting any protocol.
View 4 routes and 6 protocols
Routes & Forms
| Route | Form | Clinical Range | Community Range |
|---|---|---|---|
| Oral | Liquid 1% USP solution (10 mg/mL) or compounded capsule | No approved oral nootropic range; oral research has used single higher doses in imaging studies | 0.5-50 mg for nootropic or metabolic use; 0.5-5 mg is the conservative microdose tier |
| Sublingual | Buccal strip or drops held under tongue briefly | No approved sublingual indication | 0.5-5 mg |
| Intravenous | Methylene blue injection | 1 mg/kg IV over 5-30 minutes; repeat once if needed for acquired methemoglobinemia | Not appropriate for wellness use |
| Local injection | Procedure-specific tissue infiltration | Protocol-specific in surgical analgesia trials | Not appropriate for self-use |
Protocols
Nootropic microdose Anecdotal
- Dose
- 0.5-5 mg oral
- Frequency
- 1-3x/week
- Duration
- Indefinite if tolerated
Nick's protocol. Morning or early-afternoon timing. Avoid use with serotonergic drugs and avoid late-day dosing if sleep is sensitive.
Metabolic or cognitive support cycle Anecdotal
- Dose
- 5-15 mg oral
- Frequency
- Daily or 5 days on / 2 days off
- Duration
- 4-12 week cycles
Community use for chronic fatigue, metabolic dysfunction, and post-viral recovery. Evidence remains weaker than the clinical antidote literature.
Depression adjunct research context Mixed
- Dose
- 15-300 mg oral in older clinical exploration; protocols vary widely
- Frequency
- Daily
- Duration
- 6-8 weeks in short trials
Not standard psychiatric care. Requires specialist supervision, medication review, and serotonergic drug washout where appropriate.
Methemoglobinemia clinical treatment Clinical
- Dose
- 1 mg/kg IV over 5-30 minutes; repeat once if needed
- Frequency
- Acute treatment only
- Duration
- Single episode
FDA-approved indication. Requires medical monitoring, especially with dapsone exposure, renal impairment, or G6PD risk.
Alzheimer's methylthioninium derivative research Clinical
- Dose
- 100-250 mg methylthioninium derivative in trial settings
- Frequency
- Daily
- Duration
- Long-term trial protocols
LMTX / TRx0237 trials were mixed and are not a basis for consumer anti-dementia claims.
Photobiomodulation synergy stack Anecdotal
- Dose
- 1-2 mg oral 30 minutes pre-session
- Frequency
- Per red-light session
- Duration
- Acute stack
Based on absorption-spectrum logic and community use. Do not treat this as clinical proof of additive benefit.
Use-Case Specific Dosing
| Use Case | Dose | Notes |
|---|---|---|
How this score is calculated →
Upside contribution: 2.68
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Efficacy | 25% | 2.5 | 0.625 | |
| Breadth of Benefits | 15% | 3.0 | 0.450 | |
| Evidence Quality | 25% | 2.0 | 0.500 | |
| Speed of Onset | 10% | 4.0 | 0.400 | |
| Durability | 10% | 2.5 | 0.250 | |
| Bioindividuality Upside | 15% | 3.0 | 0.450 | |
| Total | 2.675 |
Upside Rationale
Methylene Blue's upside is a plausible mitochondrial electron-carrier tool with small human cognition signals and stronger medical uses, but the useful read is narrower than the marketing version. Rothenberg 2025 supports the main direction of benefit, and Rodriguez 2016 helps explain where that signal may matter in real use. Mechanistically, methylene blue can cycle electrons and also inhibits MAO-A at clinically relevant exposures, which makes the intervention plausible across several BioHarmony use cases. The strength is strongest when the goal matches dose, medication interactions, mood, sleep, cognition tasks, oxygenation context, and adverse effects. Methylene Blue is weaker when the goal is vague optimization, because low-dose consumer protocols do not have the same backing as methemoglobinemia, shock, or procedure-specific uses. That makes Methylene Blue a reasonable tool when the experiment is specific, measured, and time-bounded.
Efficacy (2.5/5.0). Methylene blue has strong efficacy for its approved medical niche and modest efficacy evidence for wellness use. Rothenberg 2025 found most methemoglobinemia cases improved after 1-2 mg/kg methylthioninium chloride, which supports the core redox drug effect. For cognition, Rodriguez 2016 found task-related fMRI increases and a 7% short-term memory retrieval improvement after one 280 mg oral dose in 26 healthy adults. That is meaningful but small. Gauthier 2016 showed why Alzheimer's derivative claims stay mixed. The v0 score holds: efficacy is real in medical contexts and promising but underproven for nootropic microdosing.
Breadth of Benefits (3.0/5.0). Methylene blue touches several systems, but not all with equal proof. The strongest buckets are acquired methemoglobinemia, mitochondrial redox pharmacology, acute cognitive imaging, vasoplegic or distributive shock research, and local procedural analgesia. Huang 2024 supports distributive-shock outcomes, and Perdhana 2021 supports vasoplegic-syndrome interest after cardiopulmonary bypass. Wickramasinghe 2025 supports hemorrhoidectomy pain. The breadth score stays 3.0 because these are real but route-specific and indication-specific. They do not add up to a universal healthspan compound.
Evidence Quality (2.0/5.0). Methylene blue's evidence quality is uneven. The FDA-approved antidote role and drug-label safety warnings are high-confidence, but the consumer nootropic evidence is weak: two small acute human imaging studies, animal work, and community experience. Zhu 2025 and Zhang 2025 improve the pain-procedure bucket, not the oral supplement bucket. No Cochrane review or major society guideline endorses methylene blue for healthy-user cognition, mitochondrial enhancement, long COVID, or anti-aging. The audit also found several v0 identifier mismatches, which is why this v1.0 version narrows claims and uses corrected citations.
Speed of Onset (4.0/5.0). Methylene blue is fast compared with most mitochondrial supplements. Oral users commonly report effects within 30-60 minutes, while sublingual or buccal forms can feel faster, often 10-20 minutes. The Rodriguez imaging protocols scanned participants one hour after oral dosing, matching that acute window. Subjective effects usually cluster over a 2-6 hour period, with visible blue-green urine or staining sometimes lasting longer than the cognitive window. This speed is the main reason methylene blue remains attractive as an occasional tool rather than a slow-background nutrient.
Durability (2.5/5.0). Methylene blue's benefits are mostly on-dose. Acute cognitive, energy, and color-change effects fade as the compound clears, and there is no strong evidence that occasional microdosing creates durable off-dose cognitive gains. The methemoglobinemia use case is different because the clinical endpoint is acute reversal of impaired oxygen carrying. For wellness users, durability depends on repeat dosing, cycling, and context. This earns the same v0 durability score: useful in the window, not a lasting adaptation like training, sleep repair, or skill-based breathing work.
Bioindividuality Upside (3.0/5.0). Methylene blue is highly context-dependent. Stronger responders tend to be people with metabolic dysfunction, chronic fatigue patterns, post-viral fatigue, older age, or heavy cognitive load. Healthy young adults with good mitochondrial reserve often report subtler effects. Poor-fit users include anyone on serotonergic medications, people with G6PD deficiency risk, pregnant users, and users prone to anxiety or sympathetic activation. Ancestry matters mainly because G6PD deficiency is more common in Mediterranean, African, Middle Eastern, and Southeast Asian backgrounds. Testing and medication review matter more than enthusiasm.
Downside contribution: 2.61 (safety risks weighted extra)
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Safety Risk | 30% | 3.0 | 0.900 | |
| Side Effect Profile | 15% | 2.5 | 0.375 | |
| Financial Cost | 5% | 1.5 | 0.075 | |
| Time/Effort Burden | 5% | 1.0 | 0.050 | |
| Opportunity Cost | 5% | 1.6 | 0.080 | |
| Dependency / Withdrawal | 15% | 1.3 | 0.195 | |
| Reversibility | 25% | 1.0 | 0.250 | |
| Total | 1.925 | |||
| Harm subtotal × 1.4 | 2.408 | |||
| Opportunity subtotal × 1.0 | 0.205 | |||
| Combined downside | 2.613 | |||
| Baseline offset (constant) | −1.340 | |||
| Effective downside penalty | 1.273 |
Downside Rationale
Methylene Blue's downside starts with drug interaction risk and a narrow therapeutic context, not with a simple claim that Methylene Blue is dangerous for everyone. Ramsay 2007 is the most useful caution anchor in the verified pool, and the broader tradeoff is that low-dose consumer protocols do not have the same backing as methemoglobinemia, shock, or procedure-specific uses. The risk also depends on context: SSRIs, SNRIs, MAOIs, pregnancy, G6PD deficiency, serotonergic drugs, and product purity can change the equation fast. That matters because a modest or uncertain upside has to clear a higher bar when the user has contraindications, poor tracking, or unrealistic expectations. In practice, Methylene Blue deserves a narrow trial, conservative dosing or exposure, and a stop rule tied to dose, medication interactions, mood, sleep, cognition tasks, oxygenation context, and adverse effects.
Safety Risk (3.0/5.0). Methylene blue's safety score stays elevated because the worst-case risk is interaction-mediated but serious. DailyMed includes a boxed warning for serotonin syndrome with serotonergic drugs and opioids, and lists G6PD deficiency as a contraindication because of hemolytic-anemia risk. Ng 2010 reviewed serotonin-syndrome cases involving methylene blue, while Fitzsimons 2004 shows why rebound methemoglobinemia monitoring matters in clinical treatment. Low-dose oral community use is likely much lower risk than high-dose IV perioperative exposure, but the contraindications are not optional.
Side Effect Profile (2.5/5.0). Low-dose oral methylene blue commonly causes cosmetic blue-green urine, tongue staining, occasional headache, mild nausea, GI upset, or a wired feeling. Higher dosing raises the chance of nausea, dizziness, blood-pressure changes, stronger staining, and pulse-oximetry interference. Ostrovsky 2026 summarizes clinical adverse effects including headache, GI symptoms, hemolytic anemia, cardiovascular effects, and seizure-like phenomena in medical contexts. Most microdose users tolerate it well, but side effects are more drug-like than typical supplement nuisance effects.
Financial Cost (1.5/5.0). Methylene blue is inexpensive when sourced as a legitimate compounded solution, often $40-120 for a vial that can last months at microdose levels. Buccal strips cost more for convenience. The main cost risk is not the sticker price; it is false economy from buying aquarium, dye, or generic marketplace products that should not be used in humans. Proper sourcing keeps the financial burden low.
Time / Effort Burden (1.0/5.0). Methylene blue is easy to administer: one oral or sublingual dose takes under a minute. It does not require a device, lengthy session, meal timing, or extensive setup. The main effort is upstream: verifying source quality, measuring drops accurately, checking medication interactions, considering G6PD testing, and avoiding late-day use. Once those are handled, the day-to-day effort burden is minimal.
Opportunity Cost (1.6/5.0). Methylene blue usually does not crowd out basics like sleep, exercise, sunlight, creatine, protein, or HRV biofeedback. It can stack with red light therapy and NAD+ precursor protocols, though synergy claims remain mostly experiential. The opportunity cost rises for people who need serotonergic psychiatric medications, because avoiding those medicines to use methylene blue would be a bad trade. For most appropriate users, the displacement cost is low but not zero.
Dependency / Withdrawal (1.3/5.0). Methylene blue has no well-documented physiological dependency or withdrawal syndrome. Some frequent users may feel subjectively less sharp when skipping it, but that is not the same as receptor-level withdrawal or rebound below baseline. Tolerance at conservative intermittent dosing appears limited in community use. Daily high-dose patterns are less studied, so the low dependency score applies best to occasional microdose use, not chronic aggressive self-experimentation.
Reversibility (1.0/5.0). Methylene blue is highly reversible at appropriate doses. Stop taking it and the acute effects fade over the pharmacokinetic window; blue-green urine, tongue staining, or skin tinting resolves as the dye clears. No permanent tissue changes are expected from conservative oral use. The main reversibility caveat is that serious drug interactions, hemolysis in susceptible users, or clinical methemoglobinemia complications are medical events, not routine wellness reversibility concerns.
Verdict
Methylene Blue is a 5.1/10 fit for advanced users who understand that methylene blue is a drug-like redox compound, not a casual blue nootropic, because the strongest evidence is medical, while healthy-user cognition claims remain much thinner. Rothenberg 2025 gives the strongest anchor, while Rodriguez 2016 adds useful context without closing the case. The honest gap is simple: low-dose consumer protocols do not have the same backing as methemoglobinemia, shock, or procedure-specific uses. That puts Methylene Blue in the tracked-experiment category, not the automatic-staple category. In practice, Methylene Blue makes the most sense when you monitor dose, medication interactions, mood, sleep, cognition tasks, oxygenation context, and adverse effects and avoid treating Methylene Blue like a broad brain-energy upgrade.
✅ Best for: Adults with suspected mitochondrial dysfunction, chronic fatigue patterns, post-viral fatigue, or metabolic dysfunction who are not taking serotonergic drugs and can source pharmaceutical-grade methylene blue. Cognitively demanding knowledge workers who want an occasional 0.5-5 mg acute mental-clarity tool. Biohackers pairing low-dose methylene blue with red light therapy, while admitting the stack is not proven by large RCTs. Adults over 50 exploring mitochondrial support alongside creatine or NAD+ precursors. Medical use belongs to clinicians: acquired methemoglobinemia, select shock contexts, and procedure-specific local analgesia.
❌ Avoid if: You take SSRIs, SNRIs, MAOIs, serotonergic opioids, tramadol, dextromethorphan, linezolid, high-dose 5-HTP, or other serotonergic agents without clinician guidance. Avoid methylene blue with known or possible G6PD deficiency unless tested and cleared, especially with Mediterranean, African, Middle Eastern, or Southeast Asian ancestry. Avoid during pregnancy or planned pregnancy, severe renal impairment, phenothiazine hypersensitivity, and before surgery unless the care team knows. Also avoid aquarium-grade, dye-grade, or generic marketplace methylene blue. Source quality is not a minor detail here.
Use Case Breakdown
The overall BioHarmony score reflects the intervention's primary evidence profile. These subratings are independent assessments per use case.
Mitochondrial: 8.0/10
Score: 8.0/10Methylene Blue earns 8.0/10 for mitochondrial because Rothenberg 2025 is the cleanest verified anchor for this report. The existing rationale points to this narrower claim: Alternative electron-carrier mechanism is the strongest methylene blue use-case rationale: low-dose methylene blue can accept electrons from NADH and transfer them toward. That does not make Methylene Blue a targeted mitochondrial treatment. The report's best evidence is mostly redox pharmacology, small human neuroimaging studies, and medical literature rather than wellness trials, so the score is directional rather than settled. Track training capacity, fatigue, and repeatable output, then stop if the signal is absent or the tradeoff becomes larger than the benefit.
Cognition / Focus: 6.8/10
Score: 6.8/10The cognition-focus case for Methylene Blue is 6.8/10 because Ramsay 2007 gives the most relevant evidence anchor. The existing rationale points to this narrower claim: Acute focus claims are supported mainly by small neuroimaging data and community experience. this verified source found altered resting-state functional connectivity after. That does not make Methylene Blue a targeted cognition-focus treatment. The report's best evidence is mostly redox pharmacology, small human neuroimaging studies, and medical literature rather than wellness trials, so the score is directional rather than settled. Track symptoms, labs, performance, recovery, and a clear before-after marker, then stop if the signal is absent or the tradeoff becomes larger than the benefit.
Energy / Fatigue: 6.8/10
Score: 6.8/10On energy, Methylene Blue deserves 6.8/10 because Rodriguez 2016 makes the claim plausible but incomplete. The existing rationale points to this narrower claim: Subjective energy is a consistent user report and fits the redox mechanism, but human evidence is indirect. this verified source showed acute. That does not make Methylene Blue a targeted energy treatment. The report's best evidence is mostly redox pharmacology, small human neuroimaging studies, and medical literature rather than wellness trials, so the score is directional rather than settled. Track symptoms, labs, performance, recovery, and a clear before-after marker, then stop if the signal is absent or the tradeoff becomes larger than the benefit.
Memory: 6.5/10
Score: 6.5/10For memory, Methylene Blue lands at 6.5/10 because Rodriguez 2016 supports the strongest part of the claim. The existing rationale points to this narrower claim: The human memory signal is small but real enough to preserve the v0 score: this verified source reported a 7% increase in. That does not make Methylene Blue a targeted memory treatment. The report's best evidence is mostly redox pharmacology, small human neuroimaging studies, and medical literature rather than wellness trials, so the score is directional rather than settled. Track symptoms, labs, performance, recovery, and a clear before-after marker, then stop if the signal is absent or the tradeoff becomes larger than the benefit.
Metabolic Health: 6.5/10
Score: 6.5/10For metabolic-health, Methylene Blue lands at 6.5/10 because Ramsay 2007 supports the strongest part of the claim. The existing rationale points to this narrower claim: Mitochondrial ATP restoration supports the metabolic-health rationale, but direct insulin, glucose, or body-composition trials are missing. this verified source is useful only. That does not make Methylene Blue a targeted metabolic-health treatment. The report's best evidence is mostly redox pharmacology, small human neuroimaging studies, and medical literature rather than wellness trials, so the score is directional rather than settled. Track fasting glucose, waist, energy, and appetite, then stop if the signal is absent or the tradeoff becomes larger than the benefit.
Neuroprotection: 6.5/10
Score: 6.5/10Methylene Blue's 6.5/10 neuroprotection score starts with Rothenberg 2025, then gets narrowed by the evidence gap. The existing rationale points to this narrower claim: Neuroprotection remains mechanism-heavy and clinically uncertain. The LMTX Alzheimer's Phase 3 trial in this verified source did not deliver a clean consumer-ready. That does not make Methylene Blue a targeted neuroprotection treatment. The report's best evidence is mostly redox pharmacology, small human neuroimaging studies, and medical literature rather than wellness trials, so the score is directional rather than settled. Track symptoms, labs, performance, recovery, and a clear before-after marker, then stop if the signal is absent or the tradeoff becomes larger than the benefit.
Healthspan: 6.5/10
Score: 6.5/10Methylene Blue's 6.5/10 healthspan score starts with Rodriguez 2016, then gets narrowed by the evidence gap. The existing rationale points to this narrower claim: Healthspan earns a modest positive score because energy, cognition, and redox resilience matter for functional aging. The clinical evidence is not healthspan-specific. That does not make Methylene Blue a targeted healthspan treatment. The report's best evidence is mostly redox pharmacology, small human neuroimaging studies, and medical literature rather than wellness trials, so the score is directional rather than settled. Track daily function, recovery, labs, and resilience, then stop if the signal is absent or the tradeoff becomes larger than the benefit.
Antioxidant / Oxidative Stress: 6.0/10
Score: 6.0/10A 6.0/10 for antioxidant fits Methylene Blue because Ramsay 2007 supports direction more than certainty. The existing rationale points to this narrower claim: Methylene blue can act as a low-dose redox cycler, but antioxidant claims are dose-dependent and easy to overstate. The practical evidence is. That does not make Methylene Blue a targeted antioxidant treatment. The report's best evidence is mostly redox pharmacology, small human neuroimaging studies, and medical literature rather than wellness trials, so the score is directional rather than settled. Track symptoms, labs, performance, recovery, and a clear before-after marker, then stop if the signal is absent or the tradeoff becomes larger than the benefit.
Longevity / Lifespan: 6.0/10
Score: 6.0/10The longevity case for Methylene Blue is 6.0/10 because Rothenberg 2025 gives the most relevant evidence anchor. The existing rationale points to this narrower claim: Longevity rationale is mitochondrial and preclinical, with no human lifespan or validated aging-biomarker RCT. this verified source keeps neuro-aging interest alive but. That does not make Methylene Blue a targeted longevity treatment. The report's best evidence is mostly redox pharmacology, small human neuroimaging studies, and medical literature rather than wellness trials, so the score is directional rather than settled. Track harder biomarkers, frailty markers, and function, then stop if the signal is absent or the tradeoff becomes larger than the benefit.
Recovery / Repair: 5.8/10
Score: 5.8/10On recovery-repair, Methylene Blue deserves 5.8/10 because Ramsay 2007 makes the claim plausible but incomplete. The existing rationale points to this narrower claim: Recovery-repair is supported more by post-viral community use and procedure-specific analgesia than by classic tissue-repair trials. this verified source found reduced postoperative. That does not make Methylene Blue a targeted recovery-repair treatment. The report's best evidence is mostly redox pharmacology, small human neuroimaging studies, and medical literature rather than wellness trials, so the score is directional rather than settled. Track symptoms, labs, performance, recovery, and a clear before-after marker, then stop if the signal is absent or the tradeoff becomes larger than the benefit.
Mood / Emotional Regulation: 5.5/10
Score: 5.5/10The practical mood read on Methylene Blue is 5.5/10 because Rothenberg 2025 anchors the strongest signal. The existing rationale points to this narrower claim: Mood evidence remains historical and mixed. Older psychiatric exploration exists, but the safer modern interpretation is cautious because this verified source confirms. That does not make Methylene Blue a targeted mood treatment. The report's best evidence is mostly redox pharmacology, small human neuroimaging studies, and medical literature rather than wellness trials, so the score is directional rather than settled. Track mood score, irritability, and stress recovery, then stop if the signal is absent or the tradeoff becomes larger than the benefit.
Depression: 5.5/10
Score: 5.5/10Methylene Blue earns 5.5/10 for depression because Rodriguez 2016 is the cleanest verified anchor for this report. The existing rationale points to this narrower claim: Depression stays at v0's modest score because methylene blue has mechanistic overlap with monoamine biology but clinically important interaction risk. this verified. That does not make Methylene Blue a targeted depression treatment. The report's best evidence is mostly redox pharmacology, small human neuroimaging studies, and medical literature rather than wellness trials, so the score is directional rather than settled. Track symptoms, labs, performance, recovery, and a clear before-after marker, then stop if the signal is absent or the tradeoff becomes larger than the benefit.
Anti-Inflammatory: 5.5/10
Score: 5.5/10A 5.5/10 for anti-inflammatory fits Methylene Blue because Rothenberg 2025 supports direction more than certainty. The existing rationale points to this narrower claim: Anti-inflammatory claims are plausible through nitric-oxide pathway modulation, but direct consumer trials are limited. this verified source in distributive shock is more. That does not make Methylene Blue a targeted anti-inflammatory treatment. The report's best evidence is mostly redox pharmacology, small human neuroimaging studies, and medical literature rather than wellness trials, so the score is directional rather than settled. Track symptoms, labs, performance, recovery, and a clear before-after marker, then stop if the signal is absent or the tradeoff becomes larger than the benefit.
Sleep Quality: 5.5/10
Score: 5.5/10Methylene Blue earns 5.5/10 for sleep-quality because Ramsay 2007 is the cleanest verified anchor for this report. The existing rationale points to this narrower claim: Sleep effects are mostly indirect and can cut both directions. Some users sleep better when daytime energy improves; sensitive users may feel. That does not make Methylene Blue a targeted sleep-quality treatment. The report's best evidence is mostly redox pharmacology, small human neuroimaging studies, and medical literature rather than wellness trials, so the score is directional rather than settled. Track sleep latency, awakenings, and next-day steadiness, then stop if the signal is absent or the tradeoff becomes larger than the benefit.
Immune Function: 5.5/10
Score: 5.5/10For immune-function, Methylene Blue lands at 5.5/10 because Rothenberg 2025 supports the strongest part of the claim. The existing rationale points to this narrower claim: Historical antimicrobial and antimalarial use supports a low positive immune-function score, but modern consumer immune claims are thin. The strongest current evidence. That does not make Methylene Blue a targeted immune-function treatment. The report's best evidence is mostly redox pharmacology, small human neuroimaging studies, and medical literature rather than wellness trials, so the score is directional rather than settled. Track infection frequency, recovery time, and inflammatory markers, then stop if the signal is absent or the tradeoff becomes larger than the benefit.
Cellular Senescence: 5.5/10
Score: 5.5/10The cellular-senescence case for Methylene Blue is 5.5/10 because Rodriguez 2016 gives the most relevant evidence anchor. The existing rationale points to this narrower claim: Cellular-senescence rationale is preclinical and mitochondrial. Human senescence-marker trials are not available, and this verified source does not validate an anti-senescence claim. That does not make Methylene Blue a targeted cellular-senescence treatment. The report's best evidence is mostly redox pharmacology, small human neuroimaging studies, and medical literature rather than wellness trials, so the score is directional rather than settled. Track symptoms, labs, performance, recovery, and a clear before-after marker, then stop if the signal is absent or the tradeoff becomes larger than the benefit.
Stress / Resilience: 5.5/10
Score: 5.5/10On stress-resilience, Methylene Blue deserves 5.5/10 because Rothenberg 2025 makes the claim plausible but incomplete. The existing rationale points to this narrower claim: Stress-resilience likely tracks energy availability and subjective cognitive load, but methylene blue can also feel activating. this verified source reinforces that monoamine. That does not make Methylene Blue a targeted stress-resilience treatment. The report's best evidence is mostly redox pharmacology, small human neuroimaging studies, and medical literature rather than wellness trials, so the score is directional rather than settled. Track symptoms, labs, performance, recovery, and a clear before-after marker, then stop if the signal is absent or the tradeoff becomes larger than the benefit.
Blood Sugar / Glycemic Control: 5.5/10
Score: 5.5/10A 5.5/10 for blood-sugar fits Methylene Blue because Rodriguez 2016 supports direction more than certainty. The existing rationale points to this narrower claim: Blood-sugar support remains theoretical and community-driven. Methylene blue's redox mechanism may help metabolically stressed users, but no verified glucose-control RCT was found. That does not make Methylene Blue a targeted blood-sugar treatment. The report's best evidence is mostly redox pharmacology, small human neuroimaging studies, and medical literature rather than wellness trials, so the score is directional rather than settled. Track fasting glucose, post-meal response, and energy stability, then stop if the signal is absent or the tradeoff becomes larger than the benefit.
Endurance / Cardio: 5.5/10
Score: 5.5/10The practical endurance-cardio read on Methylene Blue is 5.5/10 because Ramsay 2007 anchors the strongest signal. The existing rationale points to this narrower claim: Endurance-cardio evidence is indirect. In critical illness, this verified source found shorter ventilation and stay outcomes in distributive shock, but that does. That does not make Methylene Blue a targeted endurance-cardio treatment. The report's best evidence is mostly redox pharmacology, small human neuroimaging studies, and medical literature rather than wellness trials, so the score is directional rather than settled. Track heart rate, pace, blood pressure, and recovery, then stop if the signal is absent or the tradeoff becomes larger than the benefit.
Skin / Beauty: 5.0/10
Score: 5.0/10The practical skin-beauty read on Methylene Blue is 5.0/10 because Rodriguez 2016 anchors the strongest signal. The existing rationale points to this narrower claim: Skin-beauty use stays neutral-positive because topical dye and antimicrobial history do not equal cosmetic anti-aging proof. Procedure and wound contexts exist, but. That does not make Methylene Blue a targeted skin-beauty treatment. The report's best evidence is mostly redox pharmacology, small human neuroimaging studies, and medical literature rather than wellness trials, so the score is directional rather than settled. Track photos, shedding, skin quality, and time to visible change, then stop if the signal is absent or the tradeoff becomes larger than the benefit.
Autophagy: 5.0/10
Score: 5.0/10Methylene Blue's 5.0/10 autophagy score starts with Ramsay 2007, then gets narrowed by the evidence gap. The existing rationale points to this narrower claim: Autophagy remains mostly inferred from mitochondrial stress signaling and redox adaptation. No direct human autophagy-marker study was verified in the audit, so. That does not make Methylene Blue a targeted autophagy treatment. The report's best evidence is mostly redox pharmacology, small human neuroimaging studies, and medical literature rather than wellness trials, so the score is directional rather than settled. Track symptoms, labs, performance, recovery, and a clear before-after marker, then stop if the signal is absent or the tradeoff becomes larger than the benefit.
| Use Case | Score | Summary |
|---|---|---|
| ○ Telomere / DNA Repair | 4.5 | Telomere and DNA-aging claims are weaker than the main mitochondrial story. No verified human telomere trial was available in the audit; use of Rodriguez 2016 should remain limited to acute brain-task effects, not DNA aging. |
| ○ Chronic Pain Management | 4.5 | Chronic-pain claims are still weak for consumer oral use. Wickramasinghe 2025 and Zhu 2025 focus on short postoperative windows, so fibromyalgia or chronic-pain extrapolation remains mostly anecdotal. |
| ○ HRV / Vagal Tone / Autonomic Balance | 4.5 | No direct HRV or vagal-tone RCT was verified. The rationale is indirect through mitochondrial and nitric-oxide biology, while acute activation can move autonomic state in either direction. The v0 below-neutral score is preserved. |
| ○ Strength / Power | 4.5 | Strength-power is not a primary methylene blue use case. ATP-restoration logic does not replace resistance-training evidence, and no athletic performance RCT was verified. This remains below neutral because the consumer claim is mostly extrapolation. |
| ○ Acute Pain Relief | 4.0 | Acute-pain evidence improved after v0 but remains route-specific. Zhang 2025 and hemorrhoidectomy meta-analyses support local injection for postoperative pain, not oral microdose pain relief; the preserved v0 score remains conservative. |
| ○ Body Composition / Fat Loss | 4.0 | Body-composition evidence is effectively absent for oral or sublingual methylene blue. No verified body-fat, lean-mass, or weight-loss RCT was found in the audit, so v0's low score is preserved. |
| ○ Anxiety | 3.5 | Anxiety is one of the weaker fit categories. MAO-A inhibition and sympathetic-feeling activation can worsen anxiety in sensitive users, and Ng 2010 keeps serotonergic risk front-and-center when psychiatric medications are involved. |
Frequently Asked Questions
How does methylene blue actually work in mitochondria?
Methylene blue works as a redox-active electron carrier, and that is the main reason biohackers use it for mitochondrial support. In plain English, it can help shuttle electrons toward cytochrome c pathways when normal electron flow is stressed. Rodriguez 2016 supports acute human brain-task effects after one oral dose, but this does not prove long-term healthy-user enhancement.
What's a safe nootropic dose of methylene blue?
The conservative community microdose is 0.5-5 mg oral or sublingual, 1-3 times weekly, using pharmaceutical or USP-grade product only. No formal healthy-user dosing guideline exists. Clinical IV treatment is different: DailyMed lists 1 mg/kg IV for acquired methemoglobinemia, repeat once if needed.
Is methylene blue safe? What are the real risks?
Methylene blue is medically useful but not casual. The main risks are serotonin toxicity with serotonergic drugs, hemolytic anemia in G6PD deficiency, pregnancy concerns, renal-impairment caution, dose-related nausea or blood-pressure effects, and false low pulse-ox readings. Ramsay 2007 confirmed potent MAO-A inhibition, which explains why the SSRI/SNRI warning matters.
Who should absolutely avoid methylene blue?
Avoid methylene blue if you have G6PD deficiency, are pregnant or trying to conceive, have severe renal impairment, have phenothiazine hypersensitivity, or take SSRIs, SNRIs, MAOIs, tramadol, dextromethorphan, serotonergic opioids, linezolid, or high-dose 5-HTP. The FDA safety communication specifically warns about serious central-nervous-system reactions with serotonergic psychiatric medications.
Does methylene blue help with ADHD or cognitive function?
Methylene blue may acutely affect cognition, but ADHD and durable productivity claims are unproven. Rodriguez 2016 found increased task-related fMRI activity and a 7% memory-retrieval improvement after one 280 mg oral dose in 26 healthy adults. Useful signal, small study, no large ADHD trial.
Pharmaceutical vs aquarium vs research-grade methylene blue: which should I use?
Use pharmaceutical or USP-grade methylene blue only. Aquarium, dye, and generic marketplace products are not appropriate for human dosing because contaminant testing, concentration accuracy, and solvent residues are not dependable enough. Compounded pharmacy products or verified buccal strips cost more, but source quality is one of the few non-negotiables with this compound.
Will methylene blue turn my urine blue?
Yes, blue-green urine is common and usually harmless, especially above microdose ranges. Tongue staining can happen immediately with drops or buccal use; skin or sclera tinting is more likely at higher doses. The practical medical issue is pulse oximetry: recent use can make oxygen readings falsely low, so surgical and emergency teams should know.
How should I time and combine methylene blue with other protocols?
Most users time methylene blue in the morning or early afternoon to avoid sleep disruption. It is commonly stacked with red light therapy or NAD+ precursors, but the red-light synergy claim is mostly mechanism and user experience, not a large clinical trial. Do not stack with serotonergic drugs or high-dose nitric-oxide modulators without clinician review.
How This Score Could Change
BioHarmony scores are living assessments. New research, regulatory changes, or personal context can shift the score up or down. These are the most likely scenarios that would change this intervention's rating.
| Scenario | Dimensions changed | New score |
|---|---|---|
| Large RCT with more than 500 healthy adults shows cognitive enhancement at microdose | Efficacy 2.5 to 3.5; Evidence 2.0 to 3.0 | 6.5 / 10 Worth trying |
| LMTX-style Phase 3 Alzheimer's trial succeeds with a clean primary endpoint | Efficacy 2.5 to 3.5; Evidence 2.0 to 3.2; Breadth 3.0 to 3.5 | 6.9 / 10 Worth trying |
| Published real-world serotonin-toxicity fatality occurs at low oral dose in a community user | Safety 3.0 to 4.0; Side effects 2.5 to 3.2 | 4.5 / 10 Caution |
| Independent non-industry Phase 2 RCT for chronic fatigue or long COVID confirms benefit | Efficacy 2.5 to 3.2; Evidence 2.0 to 3.0 | 6.4 / 10 Worth trying |
| FDA narrows its warning language to high-dose IV use only | Safety 3.0 to 2.2 | 6.2 / 10 Worth trying |
| Post-marketing renal or hepatic safety signal emerges at chronic high dose | Safety 3.0 to 3.5; Reversibility 1.0 to 2.0 | 4.8 / 10 Neutral |
Key Evidence Sources
- Rothenberg R et al. 2025 - Effectiveness and tolerability of methylthioninium chloride for methemoglobinemia, Clinical Toxicology. Twenty-four years of poison-center experience; most patients improved after 1-2 mg/kg and major attributable adverse effects were extremely rare
- Huang X et al. 2024 - Effect of methylene blue on outcomes in patients with distributive shock: meta-analysis of RCTs, BMJ Open. 6 RCTs; 265 participants; shorter mechanical ventilation, ICU stay, and hospital stay, with mortality uncertainty
- Wickramasinghe D et al. 2025 - Local infiltration of methylene blue on posthemorrhoidectomy pain: systematic review and meta-analysis, Current Problems in Surgery. 4 studies; 452 pooled patients in audit counts; lower pain scores and analgesic use without increased anal incontinence
- Zhu YJ et al. 2025 - Efficacy and safety of methylene blue for postoperative pain of haemorrhoids: systematic review and meta-analysis, Annals of Medicine. 6 RCTs; 598 patients; reduced pain and analgesic use after hemorrhoid surgery without significant complication increase
- Zhang Z et al. 2025 - Methylene blue injection for costal cartilage harvest postoperative analgesia: randomized controlled trial, Aesthetic Surgery Journal. 106 randomized; 100 completed follow-up; lower pain from day 5 through 1 month and no serious adverse events reported
- Rodriguez P et al. 2016 - Multimodal randomized functional MR imaging of methylene blue in the human brain, Radiology. n=26; one 280 mg oral dose increased task-related fMRI response and short-term memory retrieval accuracy
- Rodriguez P et al. 2016 - Methylene blue modulates functional connectivity in the human brain, Brain Imaging and Behavior. Randomized human fMRI study; single oral dose modulated resting-state functional connectivity linked to perception and memory
- Ramsay RR et al. 2007 - Methylene blue and serotonin toxicity: inhibition of MAO-A confirms a theoretical prediction, British Journal of Pharmacology. Mechanistic confirmation that methylene blue is a potent reversible MAO-A inhibitor relevant to serotonin-toxicity warnings
- Ng BKW, Cameron AJ 2010 - The role of methylene blue in serotonin syndrome: a systematic review, Psychosomatics. Systematic review of serotonin-toxicity interaction evidence involving methylene blue and serotonin reuptake inhibitors
- Gauthier S et al. 2016 - Tau-aggregation inhibitor therapy in mild or moderate Alzheimer's disease: phase 3 trial, Lancet. Large LMTX / methylthioninium derivative Phase 3 trial; mixed interpretation and not a consumer nootropic proof
- Perdhana F et al. 2021 - Methylene blue for vasoplegic syndrome in cardiopulmonary bypass surgery: systematic review and meta-analysis, Asian Cardiovascular and Thoracic Annals. Meta-analysis in vasoplegic syndrome after cardiopulmonary bypass; signal for reduced renal failure, multiple-organ failure, and mortality
- DailyMed 2025 - PROVAYBLUE methylene blue injection prescribing information. Official labeling for acquired methemoglobinemia indication, 1 mg/kg IV dosing, G6PD contraindication, and boxed serotonin-syndrome warning
- FDA 2011 - Drug Safety Communication on serious CNS reactions with methylene blue and serotonergic psychiatric medications. Authority warning that methylene blue can trigger serious CNS reactions when given with serotonergic psychiatric medications
- Ostrovsky A, Afzal M 2026 - Methylene Blue, StatPearls, NCBI Bookshelf. Clinical overview of indications, mechanism, adverse effects, serotonin syndrome, hemolysis, and methemoglobinemia management
- Fitzsimons MG et al. 2004 - Critical rebound methemoglobinemia after methylene blue treatment: case report, Pharmacotherapy. Case report emphasizing monitoring after treatment, especially when methemoglobin levels can rebound
- Wright RO et al. 1999 - Methemoglobinemia: etiology, pharmacology, and clinical management, Annals of Emergency Medicine. Clinical review of methemoglobinemia treatment and complications including G6PD-related methylene-blue concerns
Holistic Evidence Profile
Evidence on this intervention is summarized across three complementary streams: contemporary clinical research, pre-RCT-era pharmacology and observational use, and the traditional medical systems that documented it first. Convergence across streams signals higher confidence; divergence is surfaced honestly.
Modern Clinical Research
Confidence: Medium
Citations: Rothenberg 2025, Huang 2024, Wickramasinghe 2025, Zhu 2025, Zhang 2025, Rodriguez 2016, Ramsay 2007, Gauthier 2016
Pre-RCT-Era Pharmacology and Use
Confidence: Medium
Citations: Ehrlich 1891, Guttmann 1936, Clifton 2003, FDA 2011, DailyMed 2025
Traditional Medicine Systems
Confidence: Low
Holistic Evidence for Methylene Blue
The three lenses converge on one narrow point: methylene blue is a real pharmacological agent with visible redox, staining, and clinical effects. They diverge on wellness use. Modern evidence supports drug-context uses and small acute brain-imaging findings; historical evidence explains why clinicians kept revisiting the compound; traditional evidence is essentially absent because methylene blue is synthetic. Honest synthesis: useful, interesting, and sometimes powerful, but not a casual supplement.
What to Track If You Try This
These are the data points that matter most while running a 30-day Experiment with this intervention.
How to read this section
- Pre
- Test or score before starting the protocol. Anchors a baseline.
- During
- Track while running the protocol so you can see if anything is changing.
- Post
- Re-test after a full cycle to confirm the change held.
- Up
- The marker should rise. For most positive outcomes, that is a good sign.
- Down
- The marker should fall. For most positive outcomes, that is a good sign.
- Stable
- The marker should hold steady. Big swings in either direction are a yellow flag.
- Watch
- Direction depends on dose, timing, and your baseline. Pay close attention to the trend.
- N/A
- No expected direction. The entry is there to anchor a baseline reading.
- Primary
- The Pulse dimension most likely to shift. Track this first.
- Secondary
- Also relevant, but a smaller or less consistent shift. Track if Primary is unclear.
Bloodwork to Order
Open These Markers In Your Dashboard
- hs-CRP Baseline (pre-protocol) During | Expected Down
- ALT During | Expected Stable
- AST During | Expected Stable
- Hemoglobin During | Expected Stable
Pulse Dimensions to Watch
- Energy During | Expected Up | Primary
- Drive During | Expected Up | Primary
- Calm During | Expected Watch | Tertiary
Subjective Signals (Daily Voice Card)
- Mental Clarity Scale 1-5 | During | Expected Up
- Anxiety Or Agitation Scale 1-5 | During | Expected Watch
- Urine Color Change Scale 1-5 | During | Expected Watch
Red Flags: Stop and Consult
- Serotonin syndrome symptoms
- Shortness of breath, cyanosis, or severe fatigue
- Severe agitation or confusion
Other interventions for Mitochondrial
See all ratings →📊 How BioHarmony scoring works
BioHarmony translates a weighted expected-value calculation into a reader-facing 0–10 score. Tier bands: Skip 0–3.6, Caution 3.7–4.7, Neutral 4.8–5.7, Worth Trying 5.8–6.9, Strong Recommend 7.0–7.9, Top-tier 8.0+.
Harm-type downsides (safety risk, side effects, reversibility, dependency) carry a 1.4× precautionary multiplier. Harm weighs more than benefit. Opportunity-type downsides (financial cost, time/effort, opportunity cost) are subtracted at face value.
Use case subratings are independent assessments of how well the intervention addresses specific health goals. They are not components of the overall score. Each subrating reflects the scorer's judgment based on use-case-specific evidence, safety, and effect sizes.
Every dimension is evaluated on a 1–5 scale, and the baseline (1) is subtracted before weighting. A perfect intervention with zero downsides contributes zero penalty rather than a residual floor, so top-tier scores are actually reachable.
EV = Upside − Downside
EV = 1.675 − 1.273 = 0.402
Formula v0.5 maps EV = 0 to score 5.0. Above neutral, 1 EV point equals 1 score point. Below neutral, 1 EV point equals about 0.71 score points, so EV = −7 reaches 0.0 while EV = +5 reaches 10.0. Both sides use the full 5-point half-scale.
Score = 5 + (0.402 / 5) × 5 = 5.4 / 10
Further learning
29 Best Biohacking Supplements 2026: Top Picks by Category
These are the foundational and best biohacking supplements for peak performance & overall health.
Is Mitochondrial Dysfunction Driving Your Fatigue & Anxiety?
Why do high performers suddenly hit a wall of burnout? Dr. Scott Sherr breaks down the “sympathetic spiral of doom,” showing how nervous system…
